Free Trial

NanoViricides (NNVC) Competitors

$2.12
+0.16 (+8.16%)
(As of 07/19/2024 ET)

NNVC vs. VTGN, ANIX, ACRS, SGMT, CKPT, CLRB, ETON, IFRX, AEON, and TLSA

Should you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Vistagen Therapeutics (VTGN), Anixa Biosciences (ANIX), Aclaris Therapeutics (ACRS), Sagimet Biosciences (SGMT), Checkpoint Therapeutics (CKPT), Cellectar Biosciences (CLRB), Eton Pharmaceuticals (ETON), InflaRx (IFRX), AEON Biopharma (AEON), and Tiziana Life Sciences (TLSA). These companies are all part of the "pharmaceutical preparations" industry.

NanoViricides vs.

Vistagen Therapeutics (NASDAQ:VTGN) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.

Vistagen Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 419.13%. Given NanoViricides' higher probable upside, equities analysts clearly believe Vistagen Therapeutics is more favorable than NanoViricides.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vistagen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
NanoViricides
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

NanoViricides has lower revenue, but higher earnings than Vistagen Therapeutics. NanoViricides is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vistagen Therapeutics$1.06M93.43-$29.36M-$2.07-1.77
NanoViricidesN/AN/A-$8.59M-$0.82-2.59

In the previous week, Vistagen Therapeutics and Vistagen Therapeutics both had 1 articles in the media. NanoViricides' average media sentiment score of 0.00 beat Vistagen Therapeutics' score of -0.10 indicating that Vistagen Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vistagen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NanoViricides
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Vistagen Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Vistagen Therapeutics received 281 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 72.24% of users gave Vistagen Therapeutics an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.

CompanyUnderperformOutperform
Vistagen TherapeuticsOutperform Votes
281
72.24%
Underperform Votes
108
27.76%
NanoViricidesOutperform Votes
No Votes
Underperform Votes
54
100.00%

NanoViricides has a net margin of 0.00% compared to NanoViricides' net margin of -2,759.59%. NanoViricides' return on equity of -41.94% beat Vistagen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vistagen Therapeutics-2,759.59% -41.94% -37.65%
NanoViricides N/A -74.66%-66.51%

78.4% of Vistagen Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 1.0% of Vistagen Therapeutics shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Vistagen Therapeutics beats NanoViricides on 10 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NNVC vs. The Competition

MetricNanoViricidesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$25.04M$7.08B$5.33B$18.22B
Dividend YieldN/A2.70%2.75%3.48%
P/E Ratio-2.5920.49138.5425.17
Price / SalesN/A277.862,144.6315.16
Price / CashN/A32.1936.3920.01
Price / Book1.665.734.875.06
Net Income-$8.59M$147.21M$111.99M$974.25M
7 Day Performance21.84%-2.42%-0.66%0.04%
1 Month Performance16.48%5.54%7.25%4.53%
1 Year Performance29.27%-4.12%6.30%7.30%

NanoViricides Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTGN
Vistagen Therapeutics
1.6932 of 5 stars
1.69 / 5 stars
$3.66
-1.1%
$19.00
+419.1%
+95.7%$99.04M$1.06M-1.7737News Coverage
ANIX
Anixa Biosciences
1.9851 of 5 stars
1.99 / 5 stars
$2.94
+1.0%
$7.00
+138.1%
-19.2%$94.10M$210,000.00-7.954News Coverage
ACRS
Aclaris Therapeutics
3.1868 of 5 stars
3.19 / 5 stars
$1.32
+0.8%
$22.25
+1,585.6%
-87.4%$94.06M$31.25M-1.21100
SGMT
Sagimet Biosciences
1.0529 of 5 stars
1.05 / 5 stars
$3.09
-4.0%
$35.80
+1,058.6%
-80.3%$93.91M$2M0.008Gap Down
CKPT
Checkpoint Therapeutics
3.3256 of 5 stars
3.33 / 5 stars
$2.58
flat
$22.60
+776.0%
-21.8%$92.08M$100,000.00-0.9323Analyst Forecast
CLRB
Cellectar Biosciences
1.5592 of 5 stars
1.56 / 5 stars
$2.52
-4.2%
$20.00
+693.7%
+27.3%$90.34MN/A-0.8220News Coverage
ETON
Eton Pharmaceuticals
2.4165 of 5 stars
2.42 / 5 stars
$3.50
+2.3%
$9.00
+157.1%
+16.7%$89.92M$31.64M87.5030
IFRX
InflaRx
2.6143 of 5 stars
2.61 / 5 stars
$1.52
-4.4%
$13.50
+788.2%
-62.7%$89.50M$70,000.00-1.9562
AEON
AEON Biopharma
1.0958 of 5 stars
1.10 / 5 stars
$2.25
-12.1%
$6.00
+166.7%
N/A$88.02MN/A0.0010
TLSA
Tiziana Life Sciences
0 of 5 stars
0.00 / 5 stars
$0.85
flat
N/A+26.1%$87.63MN/A0.009Gap Down

Related Companies and Tools

This page (NYSE:NNVC) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners